Previous studies have suggested that metformin might improve survival outcomes in patients with breast cancer. However, findings on the efficacy of metformin with chemotherapy or endocrine therapy are inconsistent.
Objective
To clarify the efficacy of metformin with chemotherapy or endocrine therapy in breast cancer patients according to the treatment setting, including neoadjuvant, adjuvant, and metastasis/recurrence.
Methods
We systematically searched for randomized controlled trials (RCTs) in MEDLINE, CENTRAL, and EMBASE from inception through July 2020. Overall survival (OS), progression-free survival (PFS), and hypoglycemia rate were the primary outcomes. Secondary outcomes included severe adverse events (SAEs) and relapse-free survival. We used the Grading of Recommendations Assessment, Development, and Evaluation approach and performed a meta-analysis to evaluate the efficacy and safety of metformin with chemotherapy and endocrine therapy in patients with breast cancer.
Results
Our systematic review included 412 participants from 5 trials. Metformin showed little to no difference in OS (hazard ratio [HR] = 1.13; 95% CI = 0.71-1.81; certainty of evidence [COE], moderate) and PFS (HR = 1.14; 95% CI = 0.86-1.50; COE, moderate) in patients with metastasis/recurrence. The evidence was very uncertain about the effect of metformin on survival outcomes in patients who received metformin with neoadjuvant or adjuvant treatment. Metformin showed little to no difference in hypoglycemia and SAEs.
Conclusion and Relevance
Metformin should be discouraged routinely in nondiabetic patients with metastatic/recurrent breast cancer. Further RCTs are needed to verify whether metformin with chemotherapy or endocrine therapy results in significant clinical benefits in the neoadjuvant or adjuvant setting.
AriaansGJalvingMde VriesEGEde JongS.Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells. BMC Cancer. 2017;17:232. doi:10.1186/s12885-017-3230-8
2.
GilesEDJindalSWellbergEA, et al. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res. 2018;20:50. doi:10.1186/s13058-018-0974-2
3.
DowlingRJOZakikhaniMFantusIGPollakMSonenbergN. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67:10804-10812. doi:10.1158/0008-5472.CAN-07-2310
4.
ZouYFXieCWYangSXXiongJP.AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/β-catenin signaling pathway activity. Mol Med Rep. 2017;15:899-907. doi:10.3892/mmr.2016.6094
5.
AljofanMRiethmacherD.Anticancer activity of metformin: a systematic review of the literature. Future Sci OA. 2019; 5:FSO410. doi:10.2144/fsoa-2019-0053
6.
DeAKuppusamyG.Metformin in breast cancer: preclinical and clinical evidence. Curr Probl Cancer. 2020;44:100488. doi:10.1016/j.currproblcancer.2019.06.003
7.
HirschHAIliopoulosDTsichlisPNStruhlK.Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507-7511. doi:10.1158/0008-5472.CAN-09-2994
8.
RochaGZDiasMMRopelleER, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res. 2011;17:3993-4005. doi:10.1158/1078-0432.CCR-10-2243
9.
SonnenblickAAgbor-TarhDBradburyI, et al. Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALTTO Phase III Randomized Trial. J Clin Oncol. 2017;35:1421-1429. doi:10.1200/JCO.2016.69.7722
10.
ZhaoYGongCWangZ, et al. A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer. Oncotarget. 2017;8:84224-84236. doi:10.18632/oncotarget.20478
11.
NanniOAmadoriDDe CensiA, et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer: the MYME randomized, phase 2 clinical trial. Breast Cancer Res Treat. 2019;174:433-442. doi:10.1007/s10549-018-05070-2
12.
PimentelILohmannAEEnnisM, et al. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast. 2019;48:17-23. doi:10.1016/j.breast.2019.08.003
13.
CoyleCCaffertyFHValeCLangleyRE.Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:2184-2195. doi:10.1093/annonc/mdw410
14.
WuZQuBHuangX, et al. The potential adjunctive benefit of adding metformin to standard treatment in inoperable cancer patients: a meta-analysis of randomized controlled trials. Ann Transl Med. 2020;8:1404. doi:10.21037/atm-20-4441
15.
GuyattGOxmanADAklEA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-394. doi:10.1016/j.jclinepi.2010.04.026
16.
HigginsJPThomasJChandlerJ, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0. Cochrane Collaboration; 2019. Accessed June 1, 2021. https://training.cochrane.org/handbook/archive/v6
17.
LiberatiAAltmanDGTetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. doi:10.1371/journal.pmed.1000100
18.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6: e1000097. doi:10.1371/journal.pmed.1000097
19.
SterneJACSavovićJPageMJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
20.
RevMan [Computer program]. Version 5.4. The Nordic Cochrane Centre; 2020.
21.
SantessoNGlentonCDahmP, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126-135. doi:10.1016/j.jclinepi.2019.10.014
22.
DavisSRRobinsonPJJaneF, et al. The benefits of adding metformin to tamoxifen to protect the endometrium—a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2018;89:605-612. doi:10.1111/cen.13830
23.
Martin-CastilloBPernasSDorcaJ, et al. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget. 2018;9:35687-35704. doi:10.18632/oncotarget.26286
24.
YamCEstevaFJPatelMM, et al. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Investig New Drugs. 2019;37:345-351. doi:10.1007/s10637-018-0700-z
25.
von HippelPT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15:35. doi:10.1186/s12874-015-0024-z
26.
XuHChenKJiaX, et al. Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis. Oncologist. 2015;20:1236-1244. doi:10.1634/theoncologist.2015-0096
27.
ShrierIBoivinJFSteeleRJ, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 2007;166:1203-1209. doi:10.1093/aje/kwm189
28.
Seoul National University Hospital. Neoadjuvant letrozole plus metformin vs letrozole plus placebo for ER-positive postmenopausal breast cancer. Accessed February 16, 2021. https://clinicaltrials.gov/ct2/show/NCT01589367
N.N. Petrov National Medical Research Center of Oncology. Neoadjuvant toremifene with melatonin or metformin in locally advanced breast cancer. Accessed February 16, 2021. https://clinicaltrials.gov/ct2/show/NCT02506790
31.
Qamar Khan. Randomized trial of neo-adjuvant chemotherapy with or without metformin for HER2 positive operable breast cancer. Accessed February 16, 2021. https://clinicaltrials.gov/ct2/show/NCT03238495
32.
Damanhour University. Role of adding metformin to neoadjuvant chemotherapy in patients with breast cancer (METNEO). Accessed February 16, 2021. https://clinicaltrials.gov/ct2/show/NCT04170465
33.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. Calorie restriction with or without metformin in triple negative breast cancer (BREAKFAST). Accessed February 16, 2021. https://clinicaltrials.gov/ct2/show/NCT04248998
ZhangJMaXLiY, et al. Metformin intervention against ovarian toxicity during chemotherapy for early breast cancer: study protocol for a randomized double-blind placebo-controlled trial. Maturitas. 2020;137:1-6. doi:10.1016/j.maturitas.2020.04.010
36.
PetchsilaKPrueksaritanondNInsinPYanaranopMChotikawicheanN.Effect of metformin for decreasing proliferative marker in women with endometrial cancer: a randomized double-blind placebo-controlled trial. Asian Pac J Cancer Prev. 2020;21:733-741. doi:10.31557/APJCP.2020.21.3.733
37.
LeeYJooJLeeYJ, et al. Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. Lung Cancer. 2021;151:8-15. doi:10.1016/j.lungcan.2020.11.011
38.
PartridgeAHHughesMEWarnerET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34:3308-3314. doi:10.1200/JCO.2015.65.8013
39.
MeyerhardtJAIrwinMLJonesLW, et al. Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors. JNCI Cancer Spectr. 2020;4:pkz096. doi:10.1093/jncics/pkz096
40.
KoKPMaSHYangJJ, et al. Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2015;153:361-370. doi:10.1007/s10549-015-3519-8
41.
El-HaggarSMEl-ShitanyNAMostafaMFEl-BassiounyNA.Metformin may protect nondiabetic breast cancer women from metastasis. Clin Exp Metastasis. 2016;33:339-357. doi:10.1007/s10585-016-9782-1
42.
LiubotaRCheshukVZotovO, et al. Metformin in neoadjuvant systemic therapy of breast cancer patients with metabolic syndrome. Arch Oncol. 2018;24:3. doi:10.2298/AOO180312003L
43.
JinhuaXDifaL.Comparison of FEC plus metformin and FEC alone in neoadjuvant chemotherapy among early breast cancer patients. Pract J Cancer. 2011;1:92-93.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
